In a patient with metastatic HER2 positive breast cancer who has received prior TDM1 in the adjuvant setting for residual disease, would you consider reintroduction of TDM1?

I would consider re-introduction of TDM1 in the subsequent line setting for metastatic, HER2 positive breast cancer as long as disease free interval between completion of TDM1 and breast cancer relapse is has been long enough. I typically think of 1 year or longer between relapse and completion of a...